Genetic Total Stockholder Equity vs Common Stock Analysis
GENE Stock | USD 0.77 0.00 0.00% |
Genetic Technologies financial indicator trend analysis is much more than just examining Genetic Technologies latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Genetic Technologies is a good investment. Please check the relationship between Genetic Technologies Total Stockholder Equity and its Common Stock accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.
Total Stockholder Equity vs Common Stock
Total Stockholder Equity vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Genetic Technologies Total Stockholder Equity account and Common Stock. At this time, the significance of the direction appears to have very week relationship.
The correlation between Genetic Technologies' Total Stockholder Equity and Common Stock is 0.26. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Common Stock in the same time period over historical financial statements of Genetic Technologies, assuming nothing else is changed. The correlation between historical values of Genetic Technologies' Total Stockholder Equity and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Genetic Technologies are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Total Stockholder Equity i.e., Genetic Technologies' Total Stockholder Equity and Common Stock go up and down completely randomly.
Correlation Coefficient | 0.26 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Common Stock
Most indicators from Genetic Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Genetic Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.At present, Genetic Technologies' Tax Provision is projected to decrease significantly based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 578.7K | 676.6K | 534.9K | 488.7K | Interest Income | 36.3K | 220.2K | 119.5K | 74.3K |
Genetic Technologies fundamental ratios Correlations
Click cells to compare fundamentals
Genetic Technologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Genetic Technologies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 15.6M | 23.0M | 20.8M | 14.9M | 6.2M | 5.9M | |
Other Current Liab | 806.5K | 955.5K | 1.6M | 1.3M | 1.9M | 1.0M | |
Total Current Liabilities | 1.4M | 1.4M | 3.8M | 3.3M | 4.2M | 4.4M | |
Total Stockholder Equity | 13.0M | 21.5M | 16.4M | 11.2M | 1.8M | 1.7M | |
Property Plant And Equipment Net | 440.2K | 637.7K | 953.3K | 599.2K | 264.5K | 251.3K | |
Net Debt | (13.7M) | (20.7M) | (11.1M) | (7.3M) | (145.4K) | (152.7K) | |
Retained Earnings | (135.9M) | (143.1M) | (150.2M) | (156.7M) | (166.4M) | (158.1M) | |
Cash | 14.2M | 20.9M | 11.7M | 7.9M | 1.0M | 969.6K | |
Non Current Assets Total | 440.2K | 735.6K | 6.1M | 4.2M | 2.5M | 2.4M | |
Non Currrent Assets Other | (440.2K) | (9.5M) | (6.1M) | (4.2M) | 81.7K | 85.8K | |
Cash And Short Term Investments | 14.2M | 20.9M | 11.7M | 7.9M | 1.0M | 987.4K | |
Net Receivables | 789.4K | 1.1M | 2.4M | 191.9K | 209.3K | 198.8K | |
Common Stock Total Equity | 122.4M | 125.5M | 140.1M | 153.6M | 176.6M | 89.1M | |
Common Stock Shares Outstanding | 41.6M | 2.8M | 3.1M | 3.4M | 132.2M | 138.8M | |
Liabilities And Stockholders Equity | 15.6M | 23.0M | 20.8M | 14.9M | 6.2M | 5.9M | |
Inventory | 91.4K | 76.9K | 398.2K | 325.9K | 206.5K | 196.1K | |
Other Stockholder Equity | 13.0M | 162.0M | 11.5M | 6.5M | 7.5M | 7.1M | |
Total Liab | 2.6M | 1.4M | 4.4M | 3.7M | 4.4M | 2.4M | |
Property Plant And Equipment Gross | 440.2K | 637.7K | 1.9M | 1.8M | 1.5M | 925.5K | |
Total Current Assets | 15.2M | 22.2M | 14.7M | 10.5M | 3.7M | 3.5M | |
Common Stock | 140.1M | 153.6M | 155.1M | 161.3M | 163.8M | 98.7M | |
Short Long Term Debt Total | 481.8K | 204.0K | 652.5K | 532.8K | 875.2K | 918.9K | |
Other Current Assets | 97.8K | 182.6K | 166.1K | 2.1M | 2.2M | 2.4M | |
Short Term Debt | 240.9K | 179.6K | 264.1K | 303.6K | 852.3K | 894.9K | |
Accounts Payable | 350.2K | 269.7K | 1.2M | 838.0K | 1.5M | 895.2K | |
Short Term Investments | 2.0K | 1.9K | 13.3K | 17.4K | 18.8K | 17.9K | |
Property Plant Equipment | 440.2K | 637.7K | 953.3K | 599.2K | 539.3K | 759.3K | |
Non Current Liabilities Total | 1.2M | 33.3K | 558.9K | 381.6K | 160.6K | 152.6K | |
Accumulated Other Comprehensive Income | 8.8M | 11.0M | 11.5M | 6.5M | 4.4M | 4.5M | |
Other Liab | 979.2K | 8.9K | 170.5K | 152.3K | 175.2K | 128.6K | |
Net Tangible Assets | 13.0M | 21.5M | 11.3M | 7.5M | 8.7M | 10.6M | |
Capital Lease Obligations | 429.5K | 204.0K | 652.5K | 532.8K | 231.6K | 205.1K | |
Net Invested Capital | 13.1M | 21.5M | 16.4M | 11.2M | 2.5M | 2.4M | |
Net Working Capital | 13.8M | 20.8M | 10.9M | 7.2M | (500.1K) | (475.1K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genetic Technologies is a strong investment it is important to analyze Genetic Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Genetic Technologies' future performance. For an informed investment choice regarding Genetic Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.02) | Revenue Per Share 2.19 | Quarterly Revenue Growth (0.11) | Return On Assets (0.63) | Return On Equity (1.85) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.